The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.
Hair loss treatments, ranging from topical minoxidil and finasteride to taking hormones such as estradiol or nandrolone, as well as a controversial suggestion of an orchiectomy. A hair system is also mentioned as an alternative solution.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
A 19-year-old has completed 70 days using oral and topical Minoxidil, oral finasteride, a dermaroller, and ketoconazole for hair regrowth. They are seeking feedback on the effectiveness of their treatment.
Topical spironolactone is discussed for hair loss treatment, with mentions of DIY solutions and dermatologist compounding. Users inquire about regrowth and sourcing the treatment.
The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.
The conversation discusses adjusting the isopropyl alcohol, propylene glycol, and water ratios in a topical finasteride solution for better scalp comfort and less dandruff. The user considers using 20ml IPA, 25ml PG, and 15ml water in a 60ml bottle, moving away from mixing finasteride with topical minoxidil.
The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.
A user is using homemade topical spironolactone for androgenetic alopecia and is unsure about its effectiveness due to concurrent telogen shedding. They are seeking advice on others' experiences with homemade topical spironolactone.
Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.
The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
A 21-year-old experiencing itchy and burning scalp with hair loss was diagnosed with MPB and scalp inflammation. They were prescribed Ketoconazole, Prednisone, Clindamycin, and Finasteride, and are considering trying antihistamines, dietary changes, and "nopoo" to alleviate symptoms.
Finasteride users often experience itchy scalps, which may improve over time, but many rely on ketoconazole shampoo to manage symptoms. Some users find that finasteride helps with hair shedding, but not with scalp irritation, which may require additional treatment.
The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.
The conversation discusses using a combination of DHT gel, dutasteride, pyrilutamide, and minoxidil to promote beard growth while minimizing hair loss. Users suggest consulting a doctor and considering genetic factors before proceeding.
The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.